Other Finding — Hamartoma
A hamartoma (fibroadenolipoma) is a focal area of fat and fibroglandular tissue (FGT) contained within a thin pseudocapsule. It is a benign developmental anomaly composed of the same tissue elements as normal breast — fat, glandular epithelium, and stroma — but in a disorganized arrangement.
Definition and Terminology
- Also known as fibroadenolipoma or lipofibroadenoma
- Represents a circumscribed collection of normal breast tissue elements in abnormal proportions
- The pseudocapsule is a compressed rim of surrounding breast tissue, not a true fibrous capsule
- Pathognomonic mammographic appearance: “breast within a breast” sign — a circumscribed mass containing both fat and soft tissue density surrounded by a thin radiolucent halo
MRI Appearance
Signal Characteristics
- T1W: Mixed signal — areas of high signal (fat) interspersed with intermediate signal (FGT), mirroring normal breast tissue
- T2W: Mixed signal corresponding to fat (high) and glandular components (intermediate to high); fat-suppressed sequences show suppression of the fatty components
- Post-contrast: The FGT within a hamartoma may enhance more pronouncedly than the surrounding breast FGT — this is benign and expected
- DWI: No restricted diffusion; ADC values are within normal range
Key Morphologic Features
- Pseudocapsule appears as a thin low-signal rim on all sequences
- Internal architecture recapitulates normal breast tissue (fat + FGT in varying ratios)
- Shape is typically oval or round, well-circumscribed
- Size ranges widely — from small incidental findings to large palpable masses
Enhancement Pattern
- Enhancement of the glandular component follows the same kinetics as normal surrounding FGT but may be more pronounced
- Enhancement may vary with the menstrual cycle and hormonal status, similar to background parenchymal enhancement (Background Parenchymal Enhancement)
- No unique mass-like or NME-type suspicious enhancement should be present within the hamartoma
Diagnostic Criteria
Benign if all three are met:
- Contains both fat and FGT within a pseudocapsule
- Internal tissue mirrors normal breast composition
- No unique mass or NME component within the hamartoma that differs from expected FGT enhancement
Board Pearl
Hamartoma FGT can enhance differently (including more) than surrounding breast FGT — do not mistake this for a suspicious finding. The key is: enhanced FGT within a pseudocapsule without a unique mass or NME = benign hamartoma.
Differential Diagnosis
| Entity | Distinguishing Feature |
|---|---|
| Fibroadenoma | Solid, homogeneous; lacks internal fat; T2 bright; no “breast within a breast” |
| Fat necrosis | History of trauma/surgery; oil cyst or dystrophic calcification; rim enhancement if acute |
| Lipoma | Pure fat signal, no glandular component; no enhancement |
| Phyllodes tumor | Solid, rapidly growing; cystic clefts; no internal fat |
| Carcinoma arising within hamartoma | Rare — discrete enhancing mass or NME within the hamartoma that does NOT match expected FGT pattern |
Board Pearl
The mammographic “breast within a breast” sign is pathognomonic for hamartoma and often more diagnostic than MRI. On MRI, the combination of fat + enhancing FGT within a pseudocapsule is the equivalent finding.
Pitfalls and Common Mistakes
- Over-calling enhancement as suspicious: The most common error — glandular tissue within a hamartoma enhances normally and may enhance more than surrounding FGT. This alone is not suspicious.
- Missing carcinoma within a hamartoma: Rare but reported. Look for a discrete mass or NME component that is morphologically different from the expected FGT enhancement pattern. If present, biopsy is warranted.
- Confusing with complex mass on MRI: Without fat-suppressed sequences, the mixed signal may simulate a complex cystic-solid mass. Always check fat-suppressed images for internal fat confirmation.
- Underestimating size on MRI: Hamartomas can be large and may compress surrounding tissue; measure the pseudocapsule boundary.
Clinical Significance and Management
- BI-RADS 2 (benign) when classic features are present
- No follow-up or intervention required for typical hamartomas
- Surgical excision only if symptomatic (pain, cosmetic concern, or very large size)
- Malignancy within a hamartoma is exceedingly rare (<0.1%) but has been reported — carcinoma arising in the glandular component
- If any atypical feature is identified (discrete mass, suspicious NME, restricted diffusion), upgrade assessment and biopsy the atypical component
Board Pearl
Carcinoma arising within a hamartoma is rare but real. The finding that should trigger concern is a discrete mass or NME within the hamartoma that looks different from the expected FGT — not the enhancement of FGT itself.
v2025 Notes
- BI-RADS v2025 lists hamartoma under Other Findings — Typically Benign, emphasizing the pseudocapsule and mixed fat/FGT composition as the defining features
- The key v2025 language: enhancement of the glandular component may be “more pronounced” than surrounding FGT — explicitly called benign to prevent overcalling